pharma · Prostate Cancer · Hot Flush
Astellas Pharma
Astellas Pharma GmbH
Astellas Pharma clinical programs — 22 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, JP
- Employees
- 12,378
- Programs
- 22
- Drugs
- 52
- Patents
- 25
Astellas Pharma projects
22 ClinicalTrials.gov programs sponsored by Astellas Pharma.
Astellas Pharma has 22 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
2215-CL-0201
Astellas Pharma GmbH
Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy
1 trial -
2693-CL-1303
Astellas Pharma GmbH
Moderate to Severe Vasomotor Symptoms (VMS)
1 trial -
7465-CL-0301
Astellas Pharma GmbH
Locally advanced or metastatic urothelial cancer
1 trial -
8951-CL-0301
Astellas Pharma GmbH
Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
1 trial -
8951-CL-0302
Astellas Pharma GmbH
Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
1 trial -
8951-CL-0305
Astellas Pharma GmbH
Gastroesophageal Junction Adenocarcinoma, Gastric Cancer, Gastric Adenocarcinoma
1 trial -
AT132
Astellas Pharma GmbH
X-linked Myotubular Myopathy (XLMTM)
1 trial -
Avacincaptad pegol, FLUORESCEIN
Astellas Pharma GmbH
geographic atrophy
1 trial -
Mirabegron
Astellas Pharma GmbH
Neurogenic detrusor overactivity (NDO)
1 trial -
1570-CL-0101
Astellas Pharma GmbH
Advanced Solid Tumors
1 trial -
2215-CL-0603
Astellas Pharma GmbH
FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
1 trial -
5541-CL-0201
Astellas Pharma GmbH
Prostate Cancer
1 trial -
8951-CL-0103
Astellas Pharma GmbH
Advanced cancer of the stomach or the gastroesophageal junction
1 trial -
8951-CL-5201
Astellas Pharma GmbH
First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma.
1 trial -
9785-CL-0123
Astellas Pharma GmbH
Prostate Cancer
1 trial -
ASP2957
Astellas Pharma GmbH
X-linked myotubular myopathy
1 trial -
PMR-EC-1206
Astellas Pharma GmbH
Prophylaxis of primary liver, kidney, heart, lung, and intestinal organ transplant rejection
1 trial -
2138-CL-0101
Astellas Pharma GmbH
Gastroesophageal Junction (GEJ) Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma
1 trial -
2215-CL-5201
Astellas Pharma GmbH
Locally advanced or metastatic NSCLC
1 trial -
2693-CL-2101
Astellas Pharma GmbH
Hot Flush
1 trial -
A study of ASP3082 in adults with advanced solid tumors
Astellas Pharma GmbH
Solid Tumor
1 trial -
A study to find a suitable dose of ASP5834 in adults with solid tumors
Astellas Pharma GmbH
Locally advanced (unresectable) or metastatic solid tumor malignancies who harbor a KRAS mutation (G12V, G12D, G12C, G12A, G12R or G13D mutation) or KRAS amplification
1 trial
Frequently asked questions
How many clinical projects does Astellas Pharma have?
22 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.